佳辰控股(01937.HK)年度綜合收益約2.58億元 同比增加約9.6%
格隆匯3月24日丨佳辰控股(01937.HK)發佈公吿,截至2024年12月31日止年度,集團錄得綜合收益約人民幣257.8百萬元,同比增加約人民幣22.5百萬元或9.6%。綜合收益增加主要是由於硫酸鈣架空活動地板產品銷售所得的收益增加。
除税前溢利由截至2023年12月31日止年度約人民幣6.4百萬元大幅增加至截至2024年12月31日止年度約人民幣14.3百萬元,增幅約為122.5%。大幅改善主要是歸因於銷售收益及毛利率的增加,其抵銷上述銷售開支、行政開支以及合約資產及貿易應收款項及應收票據減值淨額的增加。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.